Abstract
The objectives of the study were to examine the initial, first-year anti-rheumatic outpatient therapy in patients with incident SLE, as well as the concomitant use of drugs for certain comorbidities, compared to the use in the general population. The Finnish nationwide register data on special reimbursements for medication costs was screened to identify the inception cohort of 566 adult SLE patients (87% females, mean age 46.5 ± 15.9 years) over the years 2000-2007. The patients were linked to the national Drug Purchase Register. Of those, 90% had purchased at least once some disease-modifying anti-rheumatic drugs (DMARDs) during the first year. Hydroxychloroquine was the most common (76%), followed by azathioprine (15%) and methotrexate (13%). With the exception of increase in mycophenolate mofetil, the proportions remained stable over the whole study period 2000-2007. Drugs for cardiovascular diseases, dyslipidemia, diabetes mellitus, hypothyroidism and obstructive pulmonary disease were more frequently purchased than in the sex- and age-adjusted population, with rate ratios ranging from 1.6 to 7.8. Over the years 2000-2007, almost all the patients with incident SLE in Finland started with a DMARD. Higher percentages of SLE p...Continue Reading
References
Oct 2, 1993·BMJ : British Medical Journal·P H BeardonT M MacDonald
Dec 22, 1999·Lupus·M GaubitzW Domschke
Oct 23, 2001·Arthritis and Rheumatism·J M EsdaileJ L Senécal
Jan 10, 2002·Annals of the Rheumatic Diseases·D Pyne, D A Isenberg
Oct 8, 2003·Medicine·Ricard CerveraUNKNOWN European Working Party on Systemic Lupus Erythematosus
Sep 30, 2006·Arthritis and Rheumatism·Nathalie Costedoat-ChalumeauJean-Charles Piette
May 2, 2007·Arthritis and Rheumatism·Emily C SomersAndrew J Hall
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Sep 1, 2007·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·María J MolinaLuis M Vilá
Jan 15, 2008·Autoimmunity Reviews·Andrea DoriaPiercalo Sarzi-Puttini
Jul 16, 2008·Lupus·S ChambersD Isenberg
Dec 24, 2008·Annals of the Rheumatic Diseases·G Ruiz-IrastorzaM A Khamashta
Jan 20, 2009·Rheumatology·S A ChambersD Isenberg
Mar 21, 2009·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Simone AppenzellerLilian T L Costallat
Apr 9, 2010·Lupus·J NossentT Swaak
Apr 15, 2010·Arthritis Care & Research·Gabriela SchmajukEdward Yelin
Aug 24, 2010·Scandinavian Journal of Rheumatology·V RantalaihoK Puolakka
Sep 4, 2010·Autoimmunity Reviews·Andrea DoriaLuca Iaccarino
Dec 24, 2010·Annals of the Rheumatic Diseases·M A PetriL S Magder
Dec 25, 2010·Lupus·M Oliveira-SantosE M N Albuquerque
May 18, 2011·Autoimmunity Reviews·Laurent ArnaudZahir Amoura
Jun 17, 2011·Lupus·C BengtssonO Nived
Jan 25, 2012·Rheumatology·Guillermo Ruiz-IrastorzaMunther Khamashta
Sep 5, 2012·Annals of the Rheumatic Diseases·Ben ParkerIan N Bruce
Dec 25, 2012·Annals of the Rheumatic Diseases·Andrea DoriaIsabelle Boucot
Feb 21, 2013·Seminars in Arthritis and Rheumatism·Sara R SchoenfeldKaren H Costenbader
May 2, 2013·Maturitas·Preeta Kaur Chugh
Jun 25, 2013·Journal of Cardiovascular Pharmacology·George Stojan, Michelle Petri
Apr 18, 2014·Annals of the Rheumatic Diseases·Ronald F van VollenhovenMatthias Schneider
Jan 2, 2015·Lupus Science & Medicine·Katinka AlbrechtAngela Zink
Jan 9, 2015·Medicine·Íñigo Rúa-FigueroaUNKNOWN EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology)